KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Non-Current Deffered Revenue (2019 - 2025)

Historic Non-Current Deffered Revenue for Aquestive Therapeutics (AQST) over the last 7 years, with Q3 2025 value amounting to $19.7 million.

  • Aquestive Therapeutics' Non-Current Deffered Revenue fell 297.54% to $19.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.7 million, marking a year-over-year decrease of 297.54%. This contributed to the annual value of $20.0 million for FY2024, which is 3815.12% down from last year.
  • As of Q3 2025, Aquestive Therapeutics' Non-Current Deffered Revenue stood at $19.7 million, which was down 297.54% from $19.9 million recorded in Q2 2025.
  • Aquestive Therapeutics' Non-Current Deffered Revenue's 5-year high stood at $33.1 million during Q2 2023, with a 5-year trough of $4.7 million in Q1 2021.
  • In the last 5 years, Aquestive Therapeutics' Non-Current Deffered Revenue had a median value of $19.9 million in 2025 and averaged $20.3 million.
  • In the last 5 years, Aquestive Therapeutics' Non-Current Deffered Revenue surged by 34112.61% in 2022 and then plummeted by 3821.7% in 2025.
  • Aquestive Therapeutics' Non-Current Deffered Revenue (Quarter) stood at $7.1 million in 2021, then soared by 341.13% to $31.4 million in 2022, then increased by 2.95% to $32.3 million in 2023, then tumbled by 38.15% to $20.0 million in 2024, then fell by 1.71% to $19.7 million in 2025.
  • Its Non-Current Deffered Revenue stands at $19.7 million for Q3 2025, versus $19.9 million for Q2 2025 and $19.7 million for Q1 2025.